Teva Pharmaceutical Industries Limited Sponsored ADR Stock

$17.77

3.01% day before yesterday

NYSE, Jun 06, 10:10 pm CET

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Teva Pharmaceutical Industries Limited Sponsored ADR Stock price

$17.77

+4.89 37.97% 5Y

NYSE, Closing price Fri, Jun 06 2025

+0.52 3.01%

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$20.32b
Enterprise Value	$35.27b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	46.05
EV/Sales (TTM) EV/Sales	2.12
P/S ratio (TTM) P/S ratio	1.22
P/B ratio (TTM) P/B ratio	3.22
Revenue growth (TTM) Revenue growth	3.82%
Revenue (TTM) Revenue	$16.62b
EBIT (operating result TTM) EBIT	$3.69b
Free Cash Flow (TTM) Free Cash Flow	$766.00m
Cash position	$1.70b
EPS (TTM) EPS	$-1.14
P/E forward	10.48
P/S forward	1.20
EV/Sales forward	2.08
Short interest	3.39%

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Get Started for Free Today

Teva Pharmaceutical Industries Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

9x Buy

90%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

Buy

90%

Sell

10%

Analyst Estimates with Stock Price Targets

Financial data from Teva Pharmaceutical Industries Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	16,616 16,616	4% 4% 100%
- Direct Costs	8,227 8,227	4% 4% 50%
Gross Profit	8,389 8,389	4% 4% 50%
- Selling and Administrative Expenses	3,734 3,734	5% 5% 22%
- Research and Development Expense	1,003 1,003	4% 4% 6%
EBITDA	4,718 4,718	1% 1% 28%
- Depreciation and Amortization	1,031 1,031	8% 8% 6%
EBIT (Operating Income) EBIT	3,687 3,687	1% 1% 22%
Net Profit	-1,286 -1,286	161% 161% -8%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

Neutral

Seeking Alpha

●

3 days ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Jefferies Global Healthcare Conference June 4, 2025 9:20 AM ET Company Participants Christine Fox - Executive VP of U.S. Commercial Business Eric A. Hughes - Executive VP of Global R&D and Chief Medical Officer Conference Call Participants Dennis Ding - Unidentified Company Dennis Ding Good morning.

Neutral

GlobeNewsWire

●

4 days ago

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announced tender offers (the “Offers”) to purchase for cash the outstanding notes issued by finance subsidiaries of Teva and guaranteed by Teva of the series described in the table below (the “Notes”) up...

Neutral

GlobeNewsWire

●

5 days ago

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:

More Teva Pharmaceutical Industries Limited Sponsored ADR News

Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Head office	Israel
CEO	Richard Francis
Founded	1901
Website	www.tevapharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now